A list of downloadable documents created during development.
Suggested remit: To appraise the clinical and cost effectiveness of vosoritide within its marketing authorisation for treating achondroplasia in people 4 months and over.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback